Clinical Trials Directory

Trials / Completed

CompletedNCT01067001

Minocycline HCl Extended Release Tablets 135 mg Oral Bioequivalence Study

Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover, Bioequivalence Study in Normal, Healthy, Adult, Human Subjects Under Fasting Condition.

Status
Completed
Phase
Study type
Observational
Enrollment
18 (actual)
Sponsor
Amneal Pharmaceuticals Co. India Private Limited · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

To determine single-dose oral bioequivalence of Minocycline HCl Extended Release Tablets 135 mg manufactured by Amneal Pharmaceuticals Co.(I)Pvt. Ltd., India and SOLODYN® (minocycline hydrochloride) Extended Release Tablets 135 mg Manufactured for Medicis, The Dermatology Company, Scottsdale, AZ 85256, by Wellspring Pharmaceutical Canada Corp., Oakville, Ontario L6H 1M5 in normal, healthy, adult, human subjects under fasting condition.

Detailed description

Subjects will be fasted for at least 10 hours prior to scheduled time for dosing. As per the randomization schedule, one tablet of test or reference product will be administered to each subject with 240 mL of water at ambient temperature in each period. Twenty four samples will be collected from each subject during each period. The venous blood samples (5 mL each) will be withdrawn at pre-dose (before dosing, in the morning of the day of dosing) and at 1.00, 2.00, 2.50, 3.00, 3.25, 3.50, 3.75, 4.00, 4.25, 4.50, 5.00, 5.50, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 48.00, 72.00, 96.00, and 120.00 hours after dosing. The samples collected at 48.00, 72.00, 96.00, and 120.00 hours after dosing will be on an ambulatory basis (i.e. on separate visit). After collecting the blood samples from all the subjects at each sampling time point, samples will be centrifuged under refrigeration with machine set at 3000 rpm, 10 minutes and 4oC. After centrifugation, the plasma samples will be separated and transferred into respective prelabeled polypropylene tubes. These polypropylene tubes will be stored below -20°C for a maximum period of 12 hours and then they will be stored at -70°C ± 20°C until withdrawn for analysis. Samples from all the subjects completing both periods of the study as per the approved protocol will be analyzed.

Conditions

Timeline

Start date
2009-09-01
Primary completion
2009-10-01
Completion
2009-11-01
First posted
2010-02-11
Last updated
2010-02-11

Locations

1 site across 1 country: India

Source: ClinicalTrials.gov record NCT01067001. Inclusion in this directory is not an endorsement.